Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Breast 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 22Colorectal Neoplasms 19Pancreatic Neoplasms 15Stomach Neoplasms 14Rectal Neoplasms 10Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Locally Advanced Rectal Cancer 6Carcinoma, Non-Small-Cell Lung 6Liver Neoplasms 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Sarcoma 4Melanoma 4Lung Neoplasms 4Gastrointestinal Stromal Tumors 4Endometrial Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Neoplasms 2Mesothelioma 2

Interventions

pembrolizumab 3spartalizumab 2trametinib 1tislelizumab 1palbociclib 1nazartinib 1milademetan 1enzalutamide 1devimistat 1dehydroftorafur 1canakinumab 1binimetinib 1bemarituzumab 1aldesleukin 1Specimen Handling 1Pentostatin 1Midazolam 1Methods 1Magnetic Resonance Spectroscopy 1Letrozole 1Interleukin-2 1IFL protocol 1Hydroxychloroquine 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Early Intervention, Educational 1Cyclophosphamide 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × spartalizumab × Gastrointestinal × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔